BBT: CSE

Vancouver, British Columbia, Canada – December 22, 2017: Benchmark Botanics Inc. (CSE: BBT) (the “Company” or “Benchmark“) is pleased to announce that the Company has completed the acquisition of a 10 acre land parcel (the “Stowell Property“) contiguous to the Company’s property that together comprises, in the total, 20 acres of land on which the Company’s facility is located. The acquisition was completed for a purchase price of $1,000,000 paid in cash pursuant to a Contract of Purchase and Sale dated November 30, 2017 as amended on December 15, 2017 with Claude Clifford Stowell as vendor. Mr. Stowell is the Chief Operating Officer and a director of the Company and also the President and a director of Potanicals. Prior entering into the Contract of Purchase and Sale, Mr. Stowell had leased the Stowell Property to Potanicals, and Potanicals was given a right of first refusal to purchase the Stowell Property, as disclosed in greater detail in the Company’s Listing Statement dated November 2, 2017, which is filed on SEDAR.

The purchase and sale of the land parcel is a ‘related party transaction’ within the meaning of Multilateral Instrument Protection of Minority Security Holders in Special Transactions (“MI 61- 101“) because the vendor is directors of Benchmark and Potanicals. The Company relies upon the exemption in section 5.5(b) of MI 61-101 from the requirement to obtain a formal valuation of the land parcel because the Company’s common shares are listed on the Canadian Securities Exchange and are not listed or quoted on any of the stock exchanges or markets specified in section 5.5(b). The Company also relies on the exemption contained in section 5.7(1)(a) of MI 61-101 from the requirement to obtain minority shareholder approval of the acquisition of the land parcel because neither the fair market value of the land to be purchased nor the fair market value of the consideration paid by the Company for the land exceeded 25 per cent of the Company’s market capitalization.

About Benchmark

Benchmark, through its wholly-owned subsidiary Potanicals Green Growers Inc., is a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“). The Company operates a 12,700 square foot production facility in Peachland, British Columbia and is in the design stage of a Phase II expansion of an additional 50,000 square feet of growing area. The Company intends to utilize advanced cultivation methods in its cannabis facilities to address the significant opportunities in the medical marijuana market in Canada and overseas.

For more information about Benchmark, refer to the Form 2A Listing Statement available to the
public under the Company’s profile on SEDAR at www.sedar.com and the CSE website.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”
Ping (Johnson) Zhang
Chief Executive Officer

For further information contact:
Robert Wilson
Vice President
416.604.7900

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia- (Newsfile Corp. – December 18, 2017) – Benchmark Botanics Inc. (CSE: BBT) (the “Company” or “Benchmark”) is pleased to announce that pursuant to a Contract of Purchase and Sale dated effective November 8, 2016, as amended on September 19, 2017, between the Company’s wholly-owned subsidiary Potanicals Green Growers Inc.

READ MORE

Vancouver, British Columbia- (Newsfile Corp. – December 18, 2017) – Benchmark Botanics Inc. (CSE: BBT) (the “Company” or “Benchmark“) is pleased to announce that pursuant to a Contract of Purchase and Sale dated effective November 8, 2016, as amended on September 19, 2017, between the Company’s wholly-owned subsidiary Potanicals Green Growers Inc. (“Potanicals“) as purchaser and Douglas Turner as vendor, Potanicals completed the purchase on December 15, 2017 of a 10 acres land parcel (the “Turner Property“) that comprises 50% of the total 20 acres of land on which the Company’s medical marijuana production facility located in Peachland, BC. was built. Mr. Turner is a director and the Secretary of the purchaser Potanicals. Of the total purchase price of $825,000 for the Turner Property, $225,000 was paid by Potanicals by the issuance to Mr. Turner of 450,000 shares of Potanicals at a deemed price of $0.50 per share on November 9, 2016. Potanicals and Mr. Turner had agreed that the balance of $600,000 of the purchase price would be paid by way of common shares of Potanicals at $0.90 per share prior to the reverse takeover (the “RTO“) of the Company by Potanicals, which closed on November 2, 2017, or of common shares of the resulting issuer at the corresponding price per share of the resulting issuer. This purchase agreement was more fully disclosed in the Company’s Listing Statement (the “Listing Statement”) dated November 2, 2017, which is filed on SEDAR under the Company’s profile. As Potanicals underwent a 4.5 stock split before the RTO, the corresponding price for common shares of the Company equals $0.20 per share. Accordingly, the remaining $600,000 balance of the purchase price was satisfied by the issuance of 3,000,000 common shares (the “Issued Shares”) of Benchmark at a price of $0.20 per share, as confirmed by agreement among the parties. The purchase and sale is scheduled to close on December 15, 2017. The shares to be issued to Mr. Turner will be subject to a hold period of four months and one day from the date of issuance under applicable securities laws. Mr. Turner will also deposit the shares into escrow with the Company’s transfer agent, which will held in escrow pursuant to the policies of the Canadian Securities Exchange and applicable securities laws and released on the same terms as the existing escrowed shares of Benchmark held by related persons of the Company.

The Company is also pleased to announce that Potanicals has entered into a Contract of Purchase and Sale dated November 30, 2017 as amended on December 15, 2017 with Claude Clifford Stowell as vendor for the purchase by Potanicals of the other land parcel (the “Stowell Property“) of 10 acres contiguous to the Turner Property that together comprises in the total 20 acres of land on which the Company’s facility is located. Mr. Stowell is the Chief Operating Officer and a director of the Company and also the President and a director of Potanicals. Prior entering into the Contract of Purchase and Sale, Potanicals and Mr. Stowell had entered into an agreement dated March 24, 2014, as amended on September 24, 2014, by which Potanicals as tenant had leased the Stowell Property from Mr. Stowell as landlord, and Potanicals was given a right of first refusal to purchase the leased land, as was disclosed in greater detail in the Listing Statement. The purchase price of the Stowell Property is $1,000,000 cash and the purchase and sale is also scheduled to close on December 22, 2017 or such other earlier date as may be agreed between the parties.

The purchase and sale of the two land parcels are ‘related party transactions’ within the meaning of Multilateral Instrument Protection of Minority Security Holders in Special Transactions (“MI 61-101“) because the vendors are directors and officers of either Benchmark or Potanicals or both. The Company relies upon the exemption in section 5.5(b) of MI 61-101 from the requirement to obtain a formal valuation of the land parcels because the Company’s common shares are listed on the Canadian Securities Exchange and are not listed or quoted on any of the stock exchanges or markets specified in section 5.5(b). The Company also relies on the exemption contained in section 5.7(1)(a) of MI 61-101 from the requirement to obtain minority shareholder approval of the acquisitions of the land parcels because neither the fair market value of each of the lands to be purchased nor the fair market value of the consideration paid by the Company for each parcel exceed 25 per cent of the Company’s market capitalization.

About Benchmark

Benchmark, through its wholly-owned subsidiary Potanicals GreenGrowers Inc., is a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“). The Company operates a 12,700 square foot production facility in Peachland, British Columbia and is in the design stage of a Phase II expansion of an additional 50,000 square feet of growing area. The Company intends to utilize advanced cultivation methods in its cannabis facilities to address the significant opportunities in the medical marijuana market in Canada and overseas. For more information about Benchmark, refer to the Form 2A Listing Statement available to the public under the Company’s profile on SEDAR at www.sedar.com and the CSE website.

ON BEHALF OF THE BOARD
BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”
Ping (Johnson) Zhang
Chief Executive Officer

For further information contact:
Robert Wilson
Vice President
416.604.7900

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forwardlooking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially fromthose expressed in the forwardlooking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals‘ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially fromthose currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.comand on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

November 17, 2017 – Vancouver, British Columbia / TheNewswire / Benchmark Botanics Inc. (formerly Kaiyue International Inc.) (CSE: BBT) (the “Company” or “Benchmark”) is pleased to announce that it has entered into a letter agreement (the “Letter Agreement”) with Bare Root Science Inc. (“Bare Root”) on November 17, 2017. Under the Letter Agreement, Bare Root will install and commission operation of its proprietary aeroponic system and related technologies for the Company’s contemplated 50,000 sq foot Phase II facility for a set-up fee and license fee as determined by a definitive agreement. The Letter Agreement is subject to the negotiation and finalization of more comprehensive definitive agreement to replace the Letter Agreement on or before December 15, 2017.

As described in the Company’s Listing Statement dated November 2, 2017, the start-up phase of production, as well as the soft costs associated with the Company’s Phase II expansion will be funded by the $5,270,000 private placement, which closed on November 3, 2017 concurrently upon completion of the Company’s listing on the Canadian Securities Exchange. “We are extremely excited about the agreement with Bare Roots and the imminent commencement of production at our Peachland facility. This represents the next steps in the process towards our “License to Sell” from Health Canada.” said Johnson Zhang, CEO of Benchmark. “With the successful close of funding from our private placement and CSE listing, we are immediately able to take the next steps towards expansion.”

In addition, the Company is pleased to announce the appointment of Robert Wilson as Vice-President, Corporate Development. Mr. Wilson has an extensive background in corporate finance, investment management, mergers and acquisitions. Mr. Wilson also has experience in executive management and corporate governance with a TSX-listed agricultural processing company. As part of the senior management team, Mr. Wilson will be responsible for investor communications, corporate finance and strategic initiatives.

Business of Benchmark

Benchmark, through its wholly owned subsidiary Potanicals Green Growers Inc., is a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 12,700 square foot production facility in Peachland, British Columbia and is in the design stage of a Phase II expansion of an additional 50,000 square feet of growing area. The Company intends to utilize advanced cultivation methods in its cannabis facilities to address the significant opportunities in the medical marijuana market in Canada and overseas. For more information about the business of Benchmark, refer to the Form 2A Listing Statement available to the public under the Company’s profile on SEDAR at www.sedar.com and the CSE website.

ON BEHALF OF THE BOARD

BENCHMARK BOTANICS INC.
/s/ “Ping (Johnson) Zhang” Ping (Johnson) Zhang Chief Executive Officer

For further information contact:
Robert Wilson
Vice President
416.604.7900

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements:
This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and the Company’s operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that its ACMPR License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia–(Newsfile Corp. – November 8, 2017) – Benchmark Botanics (CSE: BBT) is the latest new listing on the Canadian Securities Exchange, trading under the symbol “BBT”, having previously traded on the TSX Venture Exchange as Kaiyue International. The company acquired Potanicals Green Growers at a cost of 124,187,000 shares of Benchmark on a post-consolidated basis. InvestmentPitch Media has produced a “video news alert” which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Benchmark” in the search box. In October, Potanicals received its license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations, having started the application process back in June 2013. It has built a 12,700-square foot production facility in Peachland, British Columbia, to plant, grow and cultivate high-quality medical-grade marijuana using advanced and proprietary cultivation methods. The Peachland facility, situated on two contiguous land plots totaling 20 acres, is equipped with cutting-edge technologies that will enable efficient and reliable production of medical marijuana with harvest available on a bi-monthly basis. This facility will be Benchmark’s Phase I production facility, with additional phases contemplated upon further analysis of market demand and economics. Prior to the closing of the acquisition, Potanicals spent $4.68 million building the facility and implementing its business plan. For more information contact Johnson Zhang, CEO, at 604-375-8218 or email This email address is being protected from spambots. You need JavaScript enabled to view it.. About InvestmentPitch Media InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors. CONTACT: InvestmentPitch Media Barry Morgan, CFO This email address is being protected from spambots. You need JavaScript enabled to view it. Read more at http://www.stockhouse.com/news/press-releases/2017/11/08/cse-new-listing-benchmark-botanics-commences-trading-on-the-canadian-securities#gqyM5JoEr8vKipKb.99

Vancouver, British Columbia- (Newsfile Corp. – November 7, 2017) – Benchmark Botanics Inc. (CSE: BBT) (formerly Kaiyue International Inc.) (the “Company” or “Benchmark“) announces the granting of stock options to directors and officers of the Company for an aggregate of 8,700,000 stock options of the Company exercisable at C$0.20, being the unit price for each common share of the most recent private placement closed on November 2, 2017, effective November 7, 2017. The Options shall expire and terminate on November 6, 2022.

These stock options have been granted in accordance with the Company’s Stock Option Plan. Pursuant to this plan, the Company is authorized to grant an aggregate of up to 10% of its issued and outstanding common shares on a rolling basis. Immediately following this award of stock options the Company has issued and outstanding stock options for 8,794,456 common shares of the Company and there were 4,624,230 stock options of the Company available for future grant.

ON BEHALF OF THE BOARD
BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”
Ping (Johnson) Zhang
Chief Executive Officer

For further information contact:
Johnson Zhang
Chief Executive Officer
604.375.8218

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forwardlooking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forwardlooking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals‘ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals‘ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially fromthose currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

The common shares of Benchmark Botanics Inc. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com.

Benchmark Botanics Inc., through its wholly-owned subsidiary, Potanicals Green Growers Inc., is a licensed producer of medical marijuana under Access to Cannabis for Medical Purposes Regulations. Potanicals received its producer’s license from Health Canada on October 13, 2017. Benchmark, through Potanicals, will produce medical marijuana at its facility located in Peachland, British Columbia.

Issuer: Benchmark Botanics Inc.
Security Type: Common shares/Actions ordinaires
Symbol(s): BBT
Number of securities issued and outstanding: 134 186 852
Number of Securities reserved for issuance: 94 455
CSE Sector: Life Sciences
CUSIP: 081612 10 3
ISIN: CA081612 10 3 6
Boardlot: 500
Trading Currency: CDN$
Trading Date: November 3 2017
Other Exchange: N/A
Fiscal Year end:  December 31
Transfer Agent: TSX Trust Company

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Vancouver, British Columbia, Canada – November 3, 2017: Benchmark Botanics Inc. (formerly Kaiyue International Inc.) (CSE: BBT) (the “Company” or “Benchmark”) is pleased to announce that further to its news releases dated August 3, 2017 and October 27, 2017, it completed the acquisition of all of the issued and outstanding shares of Potanicals Green Growers Inc. (“Potanicals”) (the “Transaction”) on November 2, 2017 and the common shares of Benchmark became listed and posted for trading on the Canadian Securities Exchange (the “CSE”) on November 3, 2017.

Terms of Transaction

In consideration for acquiring all of the issued and outstanding shares of Potanicals (the “Potanicals Shares”), Benchmark issued an aggregate of 124,186,752 common shares (the “Benchmark Shares”) to the Potanicals shareholders, on a post-consolidation basis of 4.5 Benchmark Shares for each issued and outstanding Potanicals Share, which resulted in Potanicals becoming a wholly-owned subsidiary of the Company. Upon completion of the Transaction, the Company’s business has changed from mining to the licensed production of marijuana under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

On closing of the Transaction, a total of 134,186,852 common shares of Benchmark are issued and outstanding, plus 94,455 stock options to purchase post-consolidated common shares of Benchmark at a price of $0.275 per common share (the “Benchmark Options”). Following closing of the Transaction, the outstanding Benchmark Options remain in effect until they are exercised or expire pursuant to the Company’s stock option plan.

Listing of Benchmark’s Shares on the CSE

On November 1, 2017, prior to completion of the Transaction, the Company delisted its common shares from the TSX Venture Exchange. On November 3, 2017, Benchmark’s common shares commenced trading on the CSE under the symbol “BBT”.

Share Consolidation, Continuation and Name Change

Effective November 2, 2017, prior to completion of the Transaction, the Company consolidated all of its issued and outstanding common shares based on a consolidation ratio (2.1174-to-1) that resulted in the reduction of the Company’s issued and outstanding common shares to 10,000,100 common shares on a non-diluted basis, continued its legal existence from Alberta in to British Columbia, and changed its name from “Kaiyue International Inc” to “Benchmark Botanics Inc.”

Completion of Potanicals Private Placement

Also on November 2, 2017, Potanicals completed a private placement of 5,855,555 Potanicals Shares at a price of $0.90 per Potanicals Share to raise gross proceeds of $5,270,000 (the “Private Placement”). Immediately following closing of the Private Placement, Benchmark completed the Transaction effective November 2, 2017.

Business of Benchmark

The business of Benchmark is now the business of Potanicals effective as of completion of the Transaction. Potanicals was incorporated under the British Columbia Business Corporations Act in 2014 to capitalize on the significant opportunities in the medical marijuana market in Canada and overseas. Potanicals has built a 12,700 square foot production facility in Peachland, British Columbia to plant, grow and cultivate high-quality medical-grade marijuana using advanced and proprietary cultivation methods. On October 13, 2017, Potanicals received its license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

The primary specialized skill and knowledge requirement for success as a Licensed Producer of medicinal marijuana relates to cultivating the product. The Peachland facility is equipped with cutting-edge technologies that will enable efficient and reliable production of medical marijuana with harvest available on a bi-monthly basis. Prior to closing of the Transaction, Potanicals spent $4.68 million building the facility and implementing its business plan.

For more information about the business of Benchmark and Potanicals, refer to the Form 2A Listing Statement available to the public under the Company’s profile on www.sedar.com SEDAR and the CSE website.

Management of Benchmark

Prior to closing of the Transaction, all of the Company’s current directors and officers resigned. The board of directors and senior officers of Benchmark now consists of: Ping (Johnson) Zhang, Chief Executive Officer and director; Claude (Cliff) Stowell, Chief Operating Officer and director; Peter R. Hughes, director; George Dorin, director; Haifeng Liu, director; and Richard (Rick) Lee, Chief Financial Officer. For more information regarding the directors and officers, refer to the Form 2A Listing Statement available to the public under the Company’s profile on www.sedar.com SEDAR and the CSE website.

ON BEHALF OF THE BOARD
BENCHMARK BOTANICS INC.
/s/ “Ping (Johnson) Zhang”
Ping (Johnson) Zhang
Chief Executive Officer

For further information contact:
Johnson Zhang
Chief Executive Officer
604.375.8218

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, B.C. December 7, 2018 – Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (“Benchmark” or the “Company”) is pleased to provide a progress report on the Company’s Peachland Cannabis Complex.

The Company is cultivating and harvesting cannabis at its indoor Peachland Cannabis Complex.

This state-of-the-art facility is designed to include the latest cannabis cultivation technologies and the latest cannabis-related green technologies.

Along with cultivation and production, the Company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research & development and genetics.

With the increased growth and operational activities, Mr. Cliff Stowell has decided to step down from the board of directors at Benchmark and will remain as the CEO of Potanicals Green Growers Inc., Benchmark’s 100% owned subsidiary and a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR).

“Benchmark is growing and the Company’s expansion will require increased attention as the Company transitions into sales. We are very pleased that Cliff will be solely focused on our Peachland Cannabis Complex. We have successfully demonstrated our growing abilities to Health Canada and will soon be moving towards value-added cannabis products. Cliff has proven himself to be a valuable team member and we are very fortunate that he will be turning his time and energies to focus on the operations of the Peachland Cannabis Complex.,” said William Ying CEO, Benchmark Botanics.

Mr. Stowell has been a pioneer and an integral part of the cannabis industry as he was an early applicant to be granted an ACMPR license in Canada, was the founder of the original Peachland Cannabis Complex, and continues to be a major shareholder and a key member of the Company’s management team.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on its three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company’s business plan includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.

Benchmark Botanics’ 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research & development, genetics.

The Company has established several European Union partnerships including the rights to “The Bulldog” trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has entered into an agreement with Barcelona, Spain-based Green BCN Corp. (“BBG Projects”) for the development and production of new strains of cannabis plant varieties and their propagating material for sale and distribution.

For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s filings at www.sedar.com.

If you would like to be added to Benchmark Botanics’ news distribution list, please sign up following this link https://benchmarkbotanics.com/signup/ or send your email address to our Investor Relations at This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD

BENCHMARK BOTANICS INC.

/s/ “William Ying”

William Ying

Chief Executive Officer

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Vancouver, British Columbia – (Newsfile Corp. – November 9, 2018) – Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (“Benchmark” or the “Company”) is pleased to announce that it has entered into an agreement with Barcelona, Spain-based Green BCN (aka: BBG Projects) Corp. for the development and production of new strains of cannabis plant varieties and their propagating material for sale and distribution by Potanicals Green Growers Inc., 100% owned by Benchmark Botanics Inc., in Canadian and Global markets.
Since 2002, BBG Projects, who possesses expertise in the feminized technology to produce cannabis seeds, has been a leading innovator of seed genetics. BBG Projects is active in the fields of agriculture and seed cultivation in the country of Spain, with product sales in global markets.
“We are delighted to be working with BBG Projects. With over 15 years’ of collective knowledge in the development and distribution of cannabis seeds, they are broadly recognized as industry leaders in seed cultivation,” said William Ying, CEO of Benchmark Botanics Inc.. “As legalization of cannabis has become a reality in Canada, so has the demand for seed genetics. The BBG Projects’ seeding knowhow and portfolios will prove to be a very valuable advantage to Benchmark Botanics Inc. and its shareholders.”
Sergio Martinez, CEO of BBG Projects indicated: “We desire to partner with Benchmark Botanics Inc. because of their network and organization in Canada and the global cannabis industry. We are confident that Benchmark has the best platform to capitalize on the potential of the genetic products we proudly supply.”
BBG Projects agrees to deploy its proprietary techniques and know-how for cannabis seed cultivation, cloning and strain development at Benchmark’s R&D facility in Peachland, B.C.. BBG Projects also agrees to give Benchmark rights in Canada to produce and/or distribute cannabis seeds under the BBG/Benchmark collaboration agreement. BBG Projects will list Benchmark Botanics Inc. as an official distributor of products in Canada.

About BBG Projects

BBG Projects is a Spanish company with over 15 years’ experience in the development and distribution of cannabis seeds. The company is active in the fields of agriculture and seed cultivation in the country of Spain, with product sales on the global markets. BBG Projects is focused on producing high quality, commercially-unique cannabis genetics.

About Benchmark Botanics Inc.

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry. In November 2017, the Company acquired its first subsidiary, Potanicals GreenGrowers Inc. Potanicals possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retrofit for large scale cultivation expansion.
ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.
/s/ “William Ying”
William Ying
Chief Executive Officer

For Further Information
Investor Relations
Benchmark Botanics, Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005
www.benchmarkbotanics.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
Forward-Looking Statements
This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including risks related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR and the Cannabis Act; (vi) managing and maintaining growth; and (vii) unfavourable publicity or consumer perception litigation; Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

October 18, 2018 – Vancouver, B.C. – Benchmark Botanics Inc. (CSE: BBT; FSE:BBW) (“Benchmark Botanics or the “Company”) applauds the Canadian government’s legalization of recreational marijuana. Today will mark the first legal recreational marijuana sales in what is expected to be a massive market. The total cannabis market in Canada, including medical as well as recreational products is expected to generate up to $7.17 billion in total sales in 2019, according to a recent Deloitte report.

Commenting on the landmark development, Benchmark Botanical’s CEO, William Ying stated, “We are thrilled with the legalization of recreational cannabis in Canada. Benchmark Botanical is well positioned to take full advantage of the legislation. This significant milestone puts Benchmark at the forefront of the Cannabis Industry.  The advantages of legalization are that it opens a retail market in addition to a medical market, loosens regulatory restrictions for access, expands distribution, and expands the industry to billions of dollars. The cannabis industry will now evolve at a very quick pace.  Today’s legalization is another step forward for our Company as we continue to take Benchmark to new and greater levels”.

The legalization of recreational marijuana will have a tremendous positive impact on many of Benchmark businesses. The recent license agreement with the Bulldog (see news release on September 27), for example, is an evidence of our determined execution of strategies. With the use of The Bulldog trademarks, we will seek to build one of the most engaging and successful brands and develop leading products in Canada for the adult-use market. With the addition of The Bulldog trademark, which has a long-established history as one of the most well-known coffee shop brands in Amsterdam and beyond, the partnership will assist the Company to position itself in the Canadian adult-use cannabis market. The Company is continuing to make prudent investments and efforts into marketing and branding of our products for the Canadian adult-use cannabis market.”

About THE BULLDOG

THE BULLDOG is an Amsterdam-based company that owns and operates a chain of cannabis coffee shops, a five-star hostel hotel in Amsterdam, locations in Canada and a merchandising line. The Bulldog No. 90 was the first coffee shop in Amsterdam and laid the benchmark for the contemporary coffee shop. What once began in a cellar, has grown into well recognized trade- name in several countries. THE BULLDOG Amsterdam has one of the longest histories of legalized recreational cannabis business with millions of customer visits to its stores every year.

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retrofit for large scale cultivation expansion.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

/s/ “William Ying”

William Ying

Chief Executive Officer

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

 

For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s profile at www.sedar.com.

If you would like to be added to Benchmark Botanics’ news distribution list, please send your email address to This email address is being protected from spambots. You need JavaScript enabled to view it..

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Vancouver, British Columbia – (Newsfile Corp. – October 16, 2018) – Benchmark Botanics, Inc. (CSE: BBT; FSE: BBW) (“Benchmark” or the “Company”). Benchmark is pleased to announce that the results of its annual general meeting of shareholders held on October 12, 2018 (the “Meeting”). A total of 76,612,838 common shares were voted at the Meeting, representing 54.14% of the 141,514,642 common shares of the Company that were issued and outstanding as at the record date.

All the resolutions put forward by the Company were approved at the Meeting. Manning Elliott LLP, Chartered Professional Accountants, was re-appointed auditor for the ensuing year.  The number of directors for the ensuring year has been set at five. Messrs. Ping (Johnson) Zhang, Claude (Cliff) Stowell, Haifeng Liu, George Dorin and William Ying were elected directors of the Company and will hold office until the next annual meeting of the Company or until their earlier resignation or removal.

At a meeting of the board of directors of the Company held immediately following the AGM on October 12, 2018, Mr. George Dorin was elected Chairman of the Board; Mr. William Ying was appointed Chief Executive Officer of the Company; Mr. Haifeng Liu was re-appointed President; Ms. Jin Kuang was re-appointed interim Chief Financial Officer and Corporate Secretary; and Mr. Claude (Cliff) Stowell was re-appointed CEO of Potanicals Green Growers Inc., the wholly owned subsidiary of the Company. Mr. Johnson Zhang, Co-Founder and a Director of the Company, stepped down from his role as Chief Executive Officer.

“It has been a great honour to serve as the CEO of Benchmark since its inception. I take great pride in our team’s collective accomplishments and the exceptional progress we have made in such a short period of time,” said Johnson.  “At the dawn of opening of the recreational market in Canada and the numerous overseas opportunities that our Company is positioned to capitalize on, the timing is perfect to bring William on board.”

Mr. William Ying brings over 20 years of experience in capital markets and strategic planning to the Company. Since 1996, he has served at various financial institutions including Yorkton Securities, Blackmont Capital, Jordan Capital and Mackie Research Capital. In those roles, William has provided growth investment opportunities to accredited investors globally (institutional, corporate and individual), as well as advised growth-oriented companies in capital raising, M&A, corporate development and other corporate finance activities.  William also participates in the Mentor in Business program at Simon Fraser University (SFU Beedie School of Business) as a mentor to share his business experience with future business leaders.

“The Board is confident that, with William’s track record of strong leadership, deep operational knowledge and focus on delivering shareholder value, he will be the perfect compliment to our leadership team and the best candidate to lead our Company into the next phase of our rapid growth,” Johnson continued.

“I am truly honored and humbled to be installed at this position and to lead Benchmark at such an important point in the Company’s evolution.  The opportunities that lie ahead are limitless,” said William, “I look forward to working closely with you and lead the company to the next stage. We have a great team in place and I am thrilled to be leading the corporate strategy and vision to drive our venture forward.”

“Benchmark is in an exceptional position today thanks to the vision and dedication of Johnson Zhang,” said Haifeng (Leo) Liu. “On behalf of the Board of Directors, our shareholders and our staff, I would like to acknowledge and thank Johnson for his many contributions, tireless efforts and for being the key driver of our growth and success to date.”

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retrofit for large scale cultivation expansion.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

George Dorin
Chairman, the Board of Directors

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

www.benchmarkbotanics.com

 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

 

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including the generation of revenue and sales of cannabis in the adult-use market under the Cannabis Act (Canada). There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including risks related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR and the Cannabis Act; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia – (Newsfile Corp. – October 1, 2018) – Benchmark Botanics, Inc. (CSE: BBT; FSE: BBW) (“Benchmark” or the “Company”) is pleased to announce that, further to its press release dated April 10, 2018, it has entered into a definitive agreement (the “Agreement”) to supersede the letter agreement with 1139000 B.C. Ltd. (“1139”) for the development of approximately 4 acres of greenhouse operations to be located in Pitt Meadows, British Columbia (the “Property”) beneficially owned by 1139.

Under the terms of the Agreement, Benchmark has agreed, through its wholly-owned subsidiary, Potanicals Green Growers Inc. (“Potanicals”), to apply for a license under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) for the Property, and upon receipt of a license under the ACMPR will earn a 25% interest in 1139, the owner of the Property. Upon the Property being developed to a commercial stage, Benchmark will have the right to increase its ownership to 51% of 1139 in consideration for the issuance of common shares of Benchmark, such number of shares to be based on the then fair market value of 1139.

Pursuant to the Agreement, 1139 is responsible for construction of the necessary facilities on the Property in order for a license under the ACMPR to be obtained. Benchmark has agreed to indemnify 1139 for certain expenses relating to the acquisition of the Property and construction of the facilities in the event that Potanicals fails to obtain a license under the ACMPR for the Property by June 30, 2019, subject to extension in certain circumstances.

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retrofit for large scale cultivation expansion.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”

Ping (Johnson) Zhang

Chief Executive Officer

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

www.benchmarkbotanics.com

 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Vancouver, British Columbia – (Newsfile Corp. – September 27, 2018) – Benchmark Botanics, Inc. (CSE: BBT; FSE: BBW) (“Benchmark” or the “Company”). Benchmark is pleased to announce that the Company has entered into a Trademarks License Agreement (the “Agreement”) with Leidseplein Beheer B.V. (the “Licensor”), a company incorporated under the laws of the Netherlands, in which the Licensor has agreed to grant the Company use of “The Bulldog” trademark in Canada upon the terms and conditions set out in the Agreement.

Under the terms of the Agreement, the Company will pay an upfront fee of $120,000 to the Licensor, such amount to be satisfied by the issuance to the Licensor of 214,286 common shares of the Company at a price of $0.56 per share, based on the closing price of the Company’s common shares on the Canadian Securities Exchange on September 19, 2018.

As partial consideration for the license granted, the Company will pay to the Licensor royalties based on a percentage of Revenues of the products sold and services provided using “The Bulldog” trademark during the term of the Agreement within 30 days of the end of each quarter of each calendar year.

Under the Agreement, Revenue means the arm’s length gross sales received for sales of all licensed products to a third party after deduction of the sales tax and charges for freight, transportation and delivery of licensed products if these costs incurred.

Johnson Zhang, Chief Executive Officer of Benchmark, said: “This Agreement represents an important step in the Benchmark journey that both companies will realize benefits from, once the adult-use market in Canada is officially opened in 19 days, on October 17, 2018. With the use of The Bulldog trademarks, we will seek to build one of the most engaging and successful brands and develop leading products in Canada for the adult-use market.

With the addition of The Bulldog trademark, which has a long-established history as one of the most well-known coffee shop brands in Amsterdam and beyond, this agreement will assist the Company to position itself in the Canadian adult-use cannabis market. The Company is continuing to make prudent investments and efforts into marketing and branding of our products for the Canadian adult-use cannabis market.”

Johnson further commented that “the licensing of The Bulldog trademarks is only the beginning of long-term cooperation with the Licensor. Benchmark will explore other cooperation opportunities with the Licensor in the areas of strains development, branding, and marketing”.

 

About THE BULLDOG

THE BULLDOG is an Amsterdam-based company that owns and operates a chain of cannabis coffee shops, a five star hostel hotel in Amsterdam, locations in Canada and a merchandising line. The Bulldog No. 90 was the first coffee shop in Amsterdam and laid the benchmark for the contemporary coffee shop. What once began in a cellar, has grown into well recognized trade-name in several countries. THE BULLDOG Amsterdam has one of the longest histories of legalized recreational cannabis business with millions of customer visits to its stores every year.

 

 

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retrofit for large scale cultivation expansion.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”

Ping (Johnson) Zhang

Chief Executive Officer

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

www.benchmarkbotanics.com

 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including the generation of revenue and sales of cannbis in the adult-use market under the Cannabis Act (Canada). There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including risks related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR and the Cannabis Act; (vi) managing and maintaining growth; and (vii) unfavourable publicity or consumer perception litigation; Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia, Canada – September 5, 2018:

Benchmark Botanics Inc. (CSE: BBT / OTC Pink: BBHKF / FSE: BBW) (the “Company” or “Benchmark”) is pleased to announce that as of August 31, 2018, its 100% owned subsidiary, Potanicals Green Growers, Inc. (“Potanicals”), has been issued a license to sell cannabis under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) by Health Canada.

“Receiving our license to sell is the crowning milestone in our licensing journey that started in 2013. This will enable the Company to showcase its products to the global market, as well as, move to close the conversations that we have engaged in thus far with vendors in several countries.” states Mr. Zhang Johnson, CEO of Benchmark.

The license to sell under the ACMPR will permit Potanicals to sell dried cannabis.

                               

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate and sell cannabis as an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retro-fit for large scale cultivation expansion.

 

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”

Ping (Johnson) Zhang

Chief Executive Officer

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, BC, August 28, 2018 – Benchmark Botanics, Inc. (“Benchmark” or the “Company”) (CSE: BBT / US OTC: BHHKF / Frankfurt: BBW.F)

 

Benchmark is pleased to announce that it intends to complete a non-brokered private placement for aggregate gross proceeds of $2,000,000 (the “Private Placement”) with an arm’s-length party who has agreed to subscribe for 2,666,667 units of the Company (the “Units”) at $0.75 per Unit (the “Subscription Price”). The Subscription Price represents a 34% premium to Benchmark’s closing share price on August 20, 2018. Each Unit is comprised of one common share of the Company (each, a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall be exercisable into one Share at a price of $1.50 for a period of 24 months from the closing date of the Private Placement. All of the Units, Shares and Warrants will be subject to a restricted period of four months and one day from the date of closing of the Private Placement.

The Company intends to use the proceeds from the sale of the Units for general working capital purposes and the costs of setting up the Company’s extraction operations.  The Private Placement is subject to acceptance by the Canadian Securities Exchange.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Benchmark

Benchmark is a publicly traded company based out of Vancouver, British Columbia positioned to provide financing, partnership opportunities and acquisition offers to licensed producers and ancillary businesses within the global cannabis industry. With the support of our global partners, we acquired our first subsidiary, Potanicals Green Growers Inc. in November 2017. Potanicals is an approved licensed producer of cannabis under the ACMPR that is currently cultivating within a 12,700 square foot production facility.

For more information about Benchmark, refer to the Form 2A Listing Statement available to the public under the Company’s profile on SEDAR at www.sedar.com and the CSE website.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.

/s/ “Ping (Johnson) Zhang”

Ping (Johnson) Zhang

Chief Executive Officer

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 604-238-0005

www.benchmarkbotanics.com

 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, the receipt of a License to Sell under the ACMPR and the timing and completion of the Private Placement. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including risks related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; (viii) competition; and (ix) the receipt of a License to Sell under the ACMPR and closing of the Private Placement. The Company is not currently producing medical marijuana. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility and that the Private Placement may not be completed as planned or at all. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia — (The Newsfile – August 10, 2018) – Benchmark Botanics Inc. (formerly Kaiyue International Inc.) (CSE: BBT) (the “Company” or “Benchmark“) announces the granting of stock options to consultants and employees of the Company for an aggregate of 2,580,000 stock options of the Company exercisable at C$0.60, being the unit price for each common share of the most recent market price closed on August 9, 2018, effective August 9, 2018. The Options shall expire and terminate on August 8, 2023.

These stock options have been granted in accordance with the Company’s Stock Option Plan. Pursuant to this plan, the Company is authorized to grant an aggregate of up to 10% of its issued and outstanding common shares on a rolling basis. Immediately following this award of stock options the Company has issued and outstanding stock options for 9,113,333 common shares of the Company and there were 4,721,464 stock options of the Company available for future grant.

About Benchmark

Benchmark Botanics, Inc. is: “Cannabis Redefined”.

Benchmark is a publicly traded company based out of Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retro-fit for large scale cultivation expansion.

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email:

This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915

www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including the timing of completion of the closing of the purchase and sale of the greenhouse facility, if at all. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia, Canada – June 15, 2018: Benchmark Botanics Inc. (CSE: BBT / OTC Pink: BBHKF / FSE: BBW) (the “Company” or “Benchmark”) provides an update to the previously announced extension to the contract of purchase and sale for a greenhouse production center located in the lower mainland region of British Columbia. The Company has not made the additional $500,000 non-refundable deposit that was due today in order to extend the completion date from June 1 to July 16, 2018. The Company is seeking to negotiate with the vendor regarding an extension of the completion date, however there is no assurance that it will successfully secure an extension on terms acceptable to the Company or at all and in the interim the original $500,000 non-refundable deposit has been transferred to the vendor.

 

About Benchmark

Benchmark Botanics, Inc. is: “Cannabis Redefined”.

Benchmark is a publicly traded company based out of Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility.

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915

www.benchmarkbotanics.com

Dave Burwell

Vice President

The Howard Group Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: 403.221-9015

Toll Free: 1-888-221-0915

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including the timing of completion of the closing of the purchase and sale of the greenhouse facility, if at all. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; (viii) competition; (ix) Benchmark may not be able to secure an extension to the completion date for the contract for the purchase of the greenhouse on terms acceptable to Benchmark or at all; and (x) Benchmark will lose all of its original $500,000 non-refundable deposit if it does not complete the purchase of the greenhouse, face a claim for damages and the agreement to purchase the greenhouse may be terminated by the vendor. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia, Canada – July 12, 2018: Benchmark Botanics Inc. (CSE: BBT / OTC Pink: BBHKF / FSE: BBW) (the “Company” or “Benchmark”) is pleased to announce it has been issued a License To Import by Health Canada.

This import license allows Benchmark, through its 100% owned subsidiary Potanicals Green Growers, access to a wide variety of genetics and strains for production. With this permit in hand, Benchmark executed a purchase order on July 11, 2018 with Dutch Passion from the Netherlands to import over 200 seeds representing 70 different strains.

The medical profile of these strains range from very high Cannabidiol (CBD) low THC, to high-THC/low-CBD, 1:1 THC:CBD strains.  This is expected to provide the Company with a number of production options to fulfill expected current and future market demand following receipt of a license to sell.

“With the recent announcements regarding legalization of Marijuana in Canada, this license to import will allow us to further develop our product catalogue. It is a great step forward.” states Mr Zhang Johnson, CEO of Benchmark.

                           

About Benchmark

 

Benchmark is a publicly traded company based in Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retro-fit for large scale cultivation expansion.

 

Click here to sign up for the Benchmark Newsletter Feed.

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915

www.benchmarkbotanics.com

Dave Burwell

Vice President

The Howard Group Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: 403.221-9015

Toll Free: 1-888-221-0915

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including development of its product catalogue and production options for additional strains of cannabis. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia, Canada – June 13, 2018: Benchmark Botanics Inc. (CSE: BBT / OTC Pink: BBHKF / FSE: BBW) (the “Company” or “Benchmark”) announces the resignation of Mr. Richard Lee as the Chief Financial Officer of the Company effective June 8, 2018. The Company is currently assessing candidates to fill this vacancy. During the interim, the functions of the Chief Financial Officer will be filled by the Company’s Corporate Controller, Ms. Jin Kuang. Ms. Kuang has previously acted as a CFO of several Reporting Issuers.

CEO and Chairman of Benchmark, Mr. Johnson Zhang, comments “On behalf of the entire Board of Directors, I would like to thank Richard Lee for his many contributions to Benchmark and we wish him all the best in his other ventures.

 

About Benchmark

Benchmark Botanics, Inc. is: “Cannabis Redefined”.

Benchmark is a publicly traded company based out of Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating in its 12,700 square foot PHASE I indoor production facility. Benchmark is pursuing additional sites to retro-fit for large scale cultivation expansion.

 

For Further Information

Investor Relations

Benchmark Botanics, Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915

www.benchmarkbotanics.com

Dave Burwell

Vice President

The Howard Group Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: 403.221-9015

Toll Free: 1-888-221-0915

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company, including the timing of completion of the closing of the purchase and sale of the greenhouse facility, if at all. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia–(Newsfile Corp. – May 22, 2018) – Benchmark Botanics Inc. (CSE: BBT) (OTC Pink: BHHKF) (FSE: BBW) (the “Company” or “Benchmark“) announces that its Chief Operating Officer will be presenting at the SGS Canada National Roadshow: Mitigate Risk and Build Your Cannabis Business in Toronto. This talk will happen on May 25th, 2018, coinciding with Benchmark’s silver level sponsorship of the LIFT MJ Conference taking place May 25-27, 2018. More details and registration link below.

Along with other expert speakers from SGS, Calum Hughes, the Chief Operating Officer of Benchmark, will present a real-life case study on becoming a Canadian Licensed Producer. He will outline the actions taken to adhere to both ACMPR application and cultivation guidelines, including Benchmark’s approach to GMP compliance.

Benchmark is also pleased to announce that they will be hosting a 20-foot by 30-foot booth at the LIFT MJ Conference. The Benchmark team will be available at booth 925. Benchmark is currently scheduling one-to-one meetings during the conference in their boardroom meeting room. Please reserve your spot by contacting Dave Burwell at This email address is being protected from spambots. You need JavaScript enabled to view it..

Speaking Event Details

National Roadshow: Mitigate Risk and Build Your Cannabis Business
Friday, May 25, 2018
8 AM – 12 PM
InterContinental Toronto Centre Hotel, Niagara Room
225 Front Street West, Toronto, ON

Registration Deadline

Thursday, May 24, 2018 (*No cost & space is limited) — click here to register.

For more details on the conference agenda and other aspects of the conference including reservations, please visit www.sgs.ca/en/events/2018/05/cannabis-roadshow.

LIFT MJ Conference Details: Benchmark will be in Booth 925. https://liftexpo.ca/

About SGS Canada:

SGS is the world’s leading inspection, verification, testing and certification company. We are recognized as the global benchmark for quality and integrity. With more than 95,000 employees, we operate a network of more than 2,400 offices and laboratories around the world.

About Benchmark

Benchmark Botanics, Inc. is: “Cannabis Redefined”.

Benchmark is a publicly traded company based out of Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc.

Operating in Peachland, B.C., Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating its 12,700 square foot PHASE I indoor production facility. Benchmark is actively pursuing opportunities to expand its cultivation capacity.

For Further Information

Investor Relations
Benchmark Botanics, Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915
www.benchmarkbotanics.com

Dave Burwell
Vice President
The Howard Group Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 403.221-9015
Toll Free: 1-888-221-0915

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia–(Newsfile Corp. – May 18, 2018) – Benchmark Botanics Inc. (CSE: BBT) (OTC Pink: BHHKF) (FSE: BBW) (the “Company” or “Benchmark“) is pleased to announce it has engaged The Howard Group as its capital markets communications advisor and will be responsible for directing both traditional and online communications initiatives, targeting the international investor community.

The Agreement is for one year term effective May 15, 2018.  The remuneration payable to The Howard Group will be $7,500 per month plus GST.  In addition, The Howard Group has been granted one million options, 750,000 of which will vest over the following eighteen months. These options will have a three-year term and an exercise price equal to the five day moving average trading price of $1.16. The Agreement and options grant are subject to the approval of the Canadian Securities Exchange.

Zhang Johnson, CEO of Benchmark stated: “This is a great step towards keeping close communication with the Canadian and International capital markets.”

Since 1988, The Howard Group has provided comprehensive investor outreach and capital markets programs, financing assistance, business development solutions and strategic planning to public companies. To learn more about The Howard Group, visit: www.howardgroupinc.com.

In addition, The Howard Group Inc. will be providing an ongoing commentary on Benchmark’s activities through its “Insight blog.”  Interested parties are encouraged to subscribe to the commentary feed: https://howardgroupinc.com/howard-group-blog/.

About Benchmark

Benchmark Botanics, Inc. is “Cannabis Redefined”

Benchmark is a publicly traded company based out of Vancouver, British Columbia that is positioned to provide financing, partnership and acquisition opportunities to licensed producers and ancillary businesses within the global cannabis industry.

In November 2017, the Company acquired its first subsidiary, Potanicals Green Growers Inc. Operating in Peachland, B.C., Potanicals Green Growers possesses a Health Canada license to cultivate cannabis and is an Access to Cannabis for Medical Purposes (ACMPR) Licensed Producer. In its first phase of operations, Potanicals is currently cultivating its 12,700 square foot PHASE I indoor production facility. Massive expansion plans are already under way to expand to approximately 1.9 million square feet of cultivation space.

For Further Information Contact:

Investor Relations
Benchmark Botanics, Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-888-221-0915
www.benchmarkbotanics.com

Dave Burwell
Vice President
The Howard Group Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 403.221-9015
Toll Free: 1-888-221-0915

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals’ operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals’ Producer’s License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

Vancouver, British Columbia--(Newsfile Corp. - October 11, 2019) -  Benchmark Botanics, Inc. (CSE: BBT) ("Benchmark" or the "Company") a licensed producer of cannabis for the medical and adult-use recreational markets, announces its intention to cooperate with Vission Technology Inc. to develop Smart Farm Total Solution for optimizing production efficiency.

Benchmark Botanics and Vission Technology have signed a non-binding letter of intent to jointly develop a "Smart Farming System Platform" for the cannabis industry, working in collaboration to create a comprehensive farm-based solution from cultivation to sales.

​"Since inception, Benchmark has been growing its experience in the cannabis industry while actively seeking technological support in all areas of operations including farm modification and expansion, cultivation, production, processing, and sales. We will be directly involved in our project with Vission Technology, working together to develop a comprehensive solution suited for the cannabis industry supply chain, contributing to the growth of the industry," says Mr. Haifeng (Leo) Liu, President of Benchmark. "I am excited by this cross-sector cooperation and its growth potential."

According to the LOI, the two parties will cooperate in four areas:

  1. Market research: Through a pilot farm project, comprehensively track all aspects of the industry chain, accurately locate the needs and weaknesses of the cannabis industry.

  2. Technology R&D: Study the advanced facilities and technologies used in the industry and develop software products that meet the industry's needs.

  3. Platform integration: Develop a "Smart Farming System Platform" to fully achieve the integration, automation, digitization and environmental protection of cannabis production from seed to sale.

  4. Social responsibility: Comply with regulations and assist with the establishment and improvement of the social responsibility system.

Following completion, the platform will be applied to solve problems of information asymmetry in the modern cannabis industry caused by factors such as environment, circulation and government policies, which can result in economic loss. Through technological means, the solution enables cannabis businesses to achieve production efficiency and transparency using system-wide tracking and real-time data monitoring.

About Vission Technology Inc.

Vission Technology Inc is a Canadian technology company engaged in the development, production and sales of system integration, IT consulting and Big Data. The company is committed to developing an industry-leading solution that integrates GIS, BIM and AIOT into one single platform. Its founding team has a vast amount of industry experience in spatial data management and analysis, IT solutions, ERP system, AI management, Big Data processing, and many more.

About Benchmark Botanics Inc.

Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia.

Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark's 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is working with a partner to build a second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark's news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005

www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48706

Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark" or the "Company") a licensed producer of cannabis for the medical and adult-use recreational markets, is pleased to announce that its wholly-owned subsidiary, Potanicals Green Growers Inc. ("Potanicals"), has signed a Licensed Producer Supply Agreement for Non-Medical Cannabis with the Province of British Columbia.

In British Columbia (BC), Benchmark has signed an agreement with the BC Liquor Distribution Branch (BCLDB), the sole, wholesale distributor of non-medical cannabis for the province that will operate standalone, public retail stores and provide online sales.

Commenting on the signing of the cannabis supply agreement, William Ying, Benchmark's CEO, stated, "We are extremely pleased to have achieved another major milestone and to further evolve the overall growth of the organization. Benchmark is very proud to have the credentials and capabilities to offer British Columbians safe, high-quality products. We are excited to work with partners that now includes the Province of British Columbia to help ensure the success of new adult-use recreational cannabis markets."

In addition to our bulk sale license received in August 2018, in July 2019 Benchmark received notification from Health Canada that it had been granted a sales license for the following activities related to sale of cannabis:

  • a license for sale for medical purposes
  • a license for standard processing authorizing the sales of cannabis plants, cannabis plants seeds, fresh cannabis and dried cannabis products

Benchmark now has the ability to sell into provincial recreational supply chains and make direct online sales to medical cannabis clients.

Benchmark, through Potanicals, acquired its original Cultivation License in October 2017 under the Access to Cannabis for Medical Purposes Regulations.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48236

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2019) - Benchmark Botanics Inc. (CSE: BBT) (the "Company" or "Benchmark") announces the granting of stock options to a consultant of the Company for 500,000 stock options of the Company exercisable at C$0.43, being the unit price for each common share of the most recent market price closed on August 30, 2019, effective September 3, 2019. The Options shall expire and terminate on September 2, 2024. The Option shall vest and be exercisable as follows: 1/3 to vest immediately with an additional 1/3 to vest every one (1) year thereafter, such that the Options are fully vested on September 2, 2021.

These stock options have been granted in accordance with the Company's Stock Option Plan. Pursuant to this plan, the Company is authorized to grant an aggregate of up to 10% of its issued and outstanding common shares on a rolling basis. Immediately following this award of stock options the Company has issued and outstanding stock options for 9,546,666 common shares of the Company and there were 7,567,893 stock options of the Company available for future grant.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 10,000 square foot facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is working with a partner to build a second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47489

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark" or the "Company") a cannabis producer, today released its financial and operational results for the second quarter ended June 30, 2019.

2019 Q2 Highlights:

  • Definitive Investment Cooperation Agreement with China-based Zhejiang Yatai Pharmaceutical
  • $11,300,000 Private Placement Financing
  • Canada Sales License Received from Health Canada

"Benchmark continued to grow during Q2 2019. With the approvals for the joint venture with Zhejiang Yatai Pharmaceutical in place and receiving the sales license from Health Canada, Benchmark is moving forward with its business plan with the goal of increasing revenues." said William Ying, Benchmark Botanics President and CEO.

2019 Q2 RECENT DEVELOPMENTS AND SUBSEQUENT EVENTS

Developments occurring during the three months ended June 30, 2019:

Definitive Investment Cooperation Agreement with China-based Zhejiang Yatai Pharmaceutical:

On May 27, 2019, the companies signed the definitive investment cooperation agreement, whereby the parties agreed to set up the new joint venture company in Canada. The new company will have a share capital of $14 million CAD, of which Zhejiang Yatai will invest $7 million CAD cash, accounting for 50% of the new company's share capital; BBT will cause its wholly-owned subsidiary Potanicals Green Growers Inc. ("PGG") to use its existing Health Canada issued license to apply for a license for property to be acquired by the new company (the "Facility") for cannabis cultivation, processing, and sale thereon and in exchange BBT will receive 25% of the new company's share capital (with a cash equivalent of $3.5 million CAD); and Rippington Investment ("RI") will invest $3.5 million CAD, accounting for the remaining 25% of the new company's share capital. RI is a private company incorporated under the Business Corporations Act (British Columbia).

The objective of the Investment Cooperation Agreement is to explore business opportunities in the Cannabis industry, subject to compliance with Canadian Cannabis and Hemp Regulations and Act, to become involved in cultivation, manufacture, processing, and marketing of high CBD (cannabidiol) cannabis products; the cultivation and R&D of medical cannabis; and the extraction, isolation, and purification of high-CBD cannabis oil for commercial; and any other activities as approved by the Board of Directors. Future products from the joint venture company may also be marketed, sold and distributed in countries and jurisdictions where cannabis products are legal.

Private Placement

On June 6, 2019, the Company has closed its non-brokered private placement financing (the "Private Placement") of 28,250,000 units (each, a "Unit") at a price of $0.40 per Unit for total gross proceeds of $11,300,000. Each Unit is comprised of one common share of the Company (each, a "Share") and one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall be exercisable into one Share at a price of $1.00 for a period of 24 months from the closing date of the Private Placement.

Cannabis Sales License Received from Health Canada

The Company, through its 100% owned subsidiary, Potanicals Green Growers, Inc. ("Potanicals") has received a sales license from Health Canada, effective July 26, 2019.

The license allows Benchmark to supply and sell finished cannabis products to provincial governments throughout Canada and through Canada's approved distribution and retail supply chain. Benchmark will be providing recreational and medical dried cannabis, capsules and other forms of cannabis products, as the Government of Canada makes more forms of the product legal for sale and consumption later this year.

Subsequent to June 30, 2019:

Subsequent to the period end, Zhejiang Yatai has received approval and acceptance of filing from the Administrative Office of Keqiao District of Shaoxing City in China for Overseas Investment Projects to establish a joint venture company to build an industrial cannabis facility in Canada with Benchmark as planned under the Investment Cooperation Agreement.

Subsequent to the period end, Zhejiang Yatai has also received an Enterprise Overseas Investment Certificate issued by the Zhejiang Provincial Department of Commerce, allowing Zhejiang Yatai to invest and transfer funds from China in order to make their CAD$7 million investment into the new joint venture company with Benchmark.

Summary of Quarterly Results

The following table presents selected financial information from continuing operations for the most recent eight quarters:

  Q2 2019 Q1 2019 Q4 2018 Q3 2018 Q2 2018 Q1 2018 Q4 2017 Q3 2017
  Jun-30 Mar-31 Dec-31 Sep-30 Jun-30 Mar-31 Dec-31 Sep-30
Revenue 134,844 - - - - - - -
Gross profit before fair value adjustments 85,363 127,862 33,992 124,430 265,837 - - -
Gross profit 71,525 127,862 33,992 124,430 265,837 - - -
Operating expenses 1,420,243 1,503,637 1,867,845 1,620,438 1,428,320 962,715 1,560,923 194,138
Loss from operations (1,358,718) (1,375,775) (1,833,853) (1,496,008) (1,162,483) (962,715) (1,560,923) (194,138)
Other (income) expenses (19,255) (3,474) 122,450 - 500,000 - 2,179,852 -
Net loss (1,339,463) (1,372,301) (1,956,303) (1,496,008) (1,662,483) (962,715) (3,740,775) (194,138)
Loss per share - basic (0.009) (0.010) (0.014) (0.011) (0.012) (0.007) (0.094) (0.009)
Weighted average number
     of shares - Basic
146,569,351 142,576,705 140,784,569 139,627,322 138,747,974 137,234,080 39,938,045 21,127,152

 

Financial Results - Highlights for the three months ended June 30, 2019

  • Total revenue for the three months ended June 30, 2019 was $134,844 (2018 - $nil) from sales of dried cannabis to another license producer. The total quantity of cannabis sold during the three months ended June 30, 2019 was 24,517 grams (2018 - nil) at a sale price of $5.50

  • Net loss for the three months ended June 30, 2019 was $1,339,463, compared to a net loss of $1,662,483 for the three months ended June 30, 2018. The decrease in net loss for the three months ended June 30, 2019 was mainly due to the decrease in other expenses of $480,745. During the quarter ended June 30, 2018, a loss on write-off of deposit was recorded with respect to the forfeiture of the $500,000 non-refundable deposit related to a purchase and sale contract for the purchase of a greenhouse production centre.

  • EBITDA before share-based compensation expenses, Fair value changes in biological assets included in inventory sold and other inventory charges and unrealized gain on changes in fair value of biological assets ("Adjusted EBITDA") for the three months ended June 30, 2019 decreased to a negative $1,015,339 from a negative $1,143,365 for the same time period of last year.

  • During the three months ended June 30, 2019, the Company has closed its non-brokered private placement financing (the "Private Placement") of 28,250,000 units (each, a "Unit") at a price of $0.40 per Unit for total gross proceeds of $11,300,000.

  • At June 30, 2019, the Company had working capital of $10,029,080 (December 31, 2018 - $793,516).

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 10,000 square foot facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is working with a partner to build a second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/47422

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark", "BBT" or the "Company") a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that its 100% owned subsidiary, Potanicals Green Growers, Inc. ("Potanicals") has received a sales license from Health Canada, effective July 26, 2019.

The license allows Benchmark to supply and sell finished cannabis products to provincial governments throughout Canada and through Canada's distribution and retail supply chain. Benchmark will be providing recreational and medical dried cannabis, capsules and other forms of cannabis products, as the Government of Canada makes more forms of the product legal for sale and consumption later this year.

"Receiving the Health Canada sales license is of significant importance and signals a giant step forward for the growth of Benchmark," said William Ying, CEO of Benchmark Botanics. "The sales license gives the Company the ability to sell additional products and is very timely with the new legalization for the edible market soon upon us. Our sales license will allow us to enter the Canadian medical and recreational marketplaces, as well as fulfill potential international supply agreements."

Along with the recent approvals for the Zhejiang Yatai Pharmaceutical Co., Ltd. joint venture, receiving the sales license represents another key milestone in Benchmark's path toward becoming one of global leaders in the development and commercialization of cannabis and cannabis-derived products designed to support health and wellness. Since late 2017, Benchmark has secured all regulatory approvals required to harvest and sell cannabis, which has contributed to the ongoing growth and enhancement of the business.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is building a Phase II expansion of an extraction facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it..

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46740

Vancouver, British Columbia--(Newsfile Corp. - July 25, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark", "BBT" or the "Company"), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to provide an update to the news release issued by the Company on May 29, 2019, which announced that Benchmark and Zhejiang Yatai Pharmaceutical Co Ltd. (" Zhejiang Yatai" ) had signed a definitive agreement (the "Investment Cooperation Agreement") to establish a joint venture company in Canada to explore opportunities, subject to compliance with Canadian Cannabis Act and related Regulations, to cultivate, manufacture, process, and market high content cannabidiol ("CBD") cannabis products; along with the R&D of medical cannabis; and the extraction, isolation, and purification of high-CBD cannabis oil for commercial applications. Zhejiang Yatai is a publicly listed company on the Shenzhen Stock Exchange (stock code: 002370).

The Company is happy to report that Zhejiang Yatai has received approval and acceptance of filing from the Administrative Office of Keqiao District of Shaoxing City in China for Overseas Investment Projects to establish a joint venture company to build an industrial cannabis facility in Canada with Benchmark as planned under the Investment Cooperation Agreement.

Zhejiang Yatai has also received an Enterprise Overseas Investment Certificate issued by the Zhejiang Provincial Department of Commerce, allowing Zhejiang Yatai to invest and transfer funds from China in order to make their CAD$7 million investment into the new joint venture company with Benchmark.

"We are pleased to see Zhejiang Yatai diligently advanced the Investment Cooperation Agreement and welcome the approvals from the local government. We believe that this event advances the viability of the partnership and for the industrial cannabis industry" said William Ying, CEO of Benchmark Botanics. "We look forward to a prosperous and mutually beneficial partnership with Zhejiang Yatai, one of the top 500 Chinese corporations."

It is anticipated that the new joint venture company will have a share capital of CAD $14 million, of which Zhejiang Yatai will invest CAD $7 million in cash, accounting for 50% of the its share capital; BBT will cause its wholly-owned subsidiary Potanicals Green Growers Inc. to use its existing Health Canada issued license to apply for a license for property to be acquired by the new company for cannabis cultivation, processing, and sale thereon and in exchange BBT will receive 25% of the new company's share capital (with a cash equivalent of CAD$3.5 million) ; and Rippington Investment will invest CAD $3.5 million in cash, accounting for the remaining 25% of the new company's share capital.

The new joint venture company will pursue business opportunities in the development of industrial cannabis products with the focus on the medical sector and quickly implement a strategic plan to seek out new profitable pharmaceutical health and wellness supplements for the company's future growth and competitiveness.

Zhejiang Yatai will bring their significant resources and experience to the new partnership with Benchmark as follows:

  • Benchmark and Zhejiang Yatai will jointly focus on developing a European and American industrial cannabis CBD market. Both will make full use of their respective significant corporate resources, established sales channels, distribution networks, existing infrastructures and the expertise of the company's drug research and development technologies.
  • Benchmark and Zhejiang Yatai will leverage their existing resources and their respective experience in the field of drug development, promote the cultivation of high CBD content of industrial hemp cultivation, processing, marketing, research and development of medical cannabis and high purity CBD-based cannabinoids extraction, separation, purification and development.
  • Benchmark and Zhejiang Yatai will be responsible for the foreign exchanges and all other related import and export logistics in accordance with domestic and international laws.

About Zhejiang Yatai Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd. (http://en.yatai.com/), one of the top 500 China Enterprises and a publicly listed company on the Shenzhen Stock Exchange (stock code: 002370) is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Company's chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 50,000 square foot facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46539

Document for Peachland Extraction Plant Construction Project and Project Auditor

Company:Benchmark Botanics Inc.

Data: 06/28/2019          

Closing date: July 15th 2019

Contractor Enquiries Welcome

Our company is going to establish a GMP-standard cannabis oil extraction facility in Peachland, BC. This construction project is open to the market for project bidding and we invite all prospective general contractors to submit a proposal.

The GMP-standard extraction facility construction contractor (hereinafter referred to as: Contractor) shall meet the detailed requirements defined in our project bidding document. For project bidding details, all inquiries are welcome.

During the implementation of the facility construction project, the contractor shall undertake coordination and docking with all equipment and systems of the facility and arrange coordination work in advance to ensure the timely and smooth implementation of the project construction.

 

Construction Project Auditor Enquiries Welcome

For the construction of the GMP-standard cannabis oil extraction facility in Peachland, our company is now seeking a 3rd party construction project auditor.

This construction project auditor contract entails duties as a general construction supervisor with relevant qualifications entrusted by our company. The contracted individual will provide us with a construction audit service for this project. The construction audit is a review of various aspects of the project to ensure that they are performing appropriately, to control for the quality and budget of this project appropriately, and to remain in keeping with the relevant trade contracts. For additional job description details, inquiries are welcome.

 

Contact:

Kristy Xu 

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (OTC Pink: BHHKF) (FSE: BBW.F) ("Benchmark" or the "Company").

Benchmark is pleased to announce that, further to its news release of May 1, 2019, the Company has closed its non-brokered private placement financing (the "Private Placement") of 28,250,000 units (each, a "Unit") at a price of $0.40 per Unit for a total gross proceeds of $11,300,000. Each Unit is comprised of one common share of the Company (each, a "Share") and one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall be exercisable into one Share at a price of $1.00 for a period of 24 months from the closing date of the Private Placement.

The Company intends to use the proceeds from the sale of the Units for general working capital purposes and the costs of setting up the Company's extraction operations. The Private Placement is subject to acceptance by the Canadian Securities Exchange.

All securities issued in connection with the Private Placement are subject to a statutory hold period expiring four months and one day after the closing of the Private Placement. Completion of the Private Placement is subject to regulatory approval.

None of the securities issued have been registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building a second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC through a joint venture (earn-in agreement) with 1139000 BC Ltd.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has also established German commercial partnership to potentially export the Company's products into the EU markets.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com. If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it..

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005 (ext. 101)
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45370

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark", "BBT" or the "Company") a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., Ltd. ("Zhejian Yatai "), a publicly listed company on the Shenzhen Stock Exchange (stock code: 002370), to set up a joint venture company in Canada.

Subject to compliance with relevant Canadian Cannabis Laws, the new company will explore business opportunities in the Cannabis industry to become involved in cultivation, manufacture, processing, and marketing of high cannabidiol ("CBD") cannabis products; in the cultivation and R&D of medical cannabis; and in the extraction, isolation, and purification of high-CBD cannabis oil for commercial applications. This definitive agreement solidifies the terms of the Letter of Intent of Strategic Cooperation between Benchmark and Zhejian Yatai, which was reported in a news release on May 7, 2019.

"This agreement with Zhejiang Yatai is a significant milestone for Benchmark Botanics," said William Ying, CEO of Benchmark Botanics. "Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Benchmark is the perfect partner to take Zhejiang Yatai's drug research and development, production and sales in the pharmaceutical field and synergize with Benchmark's expertise in cannabis cultivation and extraction."

On May 27, 2019, the companies signed the definitive investment cooperation agreement, whereby the parties agreed to set up the new joint venture company in Canada. The new company will have a share capital of $14 million CAD, of which Zhejiang Yatai will invest $7 million CAD cash, accounting for 50% of the new company's share capital; BBT will cause its wholly-owned subsidiary Potanicals Green Growers Inc. ("PGG") to use its existing Health Canada issued license to apply for a license for property to be acquired by the new company (the "Facility") for cannabis cultivation, processing, and sale thereon and in exchange BBT will receive 25% of the new company's share capital (with a cash equivalent of $3.5 million CAD); and Rippington Investment ("RI") will invest $3.5 million CAD, accounting for the remaining 25% of the new company's share capital.

Objective of the Agreement

The objective of the Investment Cooperation Agreement is to explore business opportunities in the Cannabis industry, subject to compliance with Canadian Cannabis and Hemp Regulations and Act, to become involved in cultivation, manufacture, processing, and marketing of high CBD (cannabidiol) cannabis products; the cultivation and R&D of medical cannabis; and the extraction, isolation, and purification of high-CBD cannabis oil for commercial; and any other activities as approved by the Board of Directors. Future products from the joint venture company may also be marketed, sold and distributed in countries and jurisdictions where cannabis products are legal.

Primary Components of the Joint Venture

The company name will be YATAI & BBT Biotech Ltd.

A limited liability corporation is to be established pursuant to the laws and regulations of Canada with the company's first issue of 14 million shares will be made as follows:

  • Yatai Pharmaceutical will purchase 7,000,000 shares for $7,000,000 CAD, representing 50% of the initial issued shares. The contributions will be made in two stages. In the first stage Yatai Pharmaceutical will contribute $4 million CAD and in second stage Yatai Pharmaceutical will contribute $3 million CAD.

  • BBT will receive 3,500,000 shares, representing 25% of the initial issued shares, by causing PGG to use its existing Health Canada issued license to apply a license for the Facility for cannabis cultivation, processing, and sale. The shares will be issued at the time of the joint venture company's incorporation.

  • RI will purchase 3,500,000 shares for $3,500,000 CAD, representing 25% of the initial issued shares. The contributions will be made in two stages. In the first stage RI will contribute $2 million CAD and in second stage RI will contribute $1.5 million CAD.

The company's business scope will be to explore business opportunities in the cannabis industry, subject to compliance with the Canadian cannabis legislation and regulations, promote high content of CBD industrial hemp cultivation, cultivation, processing, marketing and medical cannabis cultivation, research and development and high purity CBD-based cannabinoid extraction, separation, purification and commercialization of multi-field applications and other activities to be determined by the company.

The joint venture company will make full use of the existing resources and the company's experience in the field of drug development, promote the cultivation of high content of CBD industrial hemp cultivation, processing, marketing, research and development of medical cannabis and high purity CBD-based cannabinoids extraction, separation, purification and development.

"We are extremely happy to have signed this agreement with Benchmark Botanics and look forward to capitalizing on the medical applications of CBD. We are delighted to have partnered with a quality organization that shares the same standards as well as a philosophy rooted in science to produce unique, safe, and quality products," said Mr. Chen, Chairman of Yatai Pharmaceutical." We will utilize all of our expertise and resources to maximize our efforts to build the company's value and a long-term successful joint venture."

The definitive agreement filings will be available on SEDAR.

About Zhejiang Yatai Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd. (http://en.yatai.com/), a publicly listed company on the Shenzhen Stock Exchange (stock code: 002370) is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Company's chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building a second facility, a 4-acre Pitt Meadows Greenhouse Operation in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it..

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45126

Vancouver, B.C. May 7, 2019 – Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC: BHHKF) ("Benchmark" or the "Company") a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co., Ltd. (“Zhejiang Yatai “), a publicly listed company on the Shenzhen Stock Exchange (stock code: 002370), to promote and conduct research and development, production, extraction and the commercial application of CBD and its derivative products for medical applications. Benchmark and Zhejiang Yatai agree to create, develop and market a variety of high content cannabinoid based (“CBD”) pharmaceuticals, natural health products and cosmetics for international markets.

“Partnering with a team that understands health-related product development from ideation to formulation, will provide Benchmark Botanics with a significant advantage as we plan for long-term success. I’m pleased to welcome Mr. Yaogen Chen and the Zhejiang Yatai team, who are already applying their expertise in the development of natural health products, drug development and molecular modeling for a variety of cannabis products,” said William Ying, CEO of Benchmark Botanics. “Their vision is impressive, and together we’ve laid out an ambitious plan to extend into international consumer markets such as health and wellness, cosmetics and nutraceuticals.”

“This is a natural progression for Zhejiang Yatai and Benchmark Botanics as Benchmark's team already have experience in growing, cultivating and processing medical cannabis. We share the same principles as well as a philosophy rooted in science and geared for the production of unique, safe, and quality products,” said Mr. Chen, Chairman of Yatai Pharmaceutical. “We’ve already established a multi-year plan and we’re preparing our fully-equipped, state-of-the-art facility in Canada to capitalize the medical applications of CBD.”   

The companies agree to establish a new joint venture company in Canada to fully integrate Zhejiang Yatai 's advantages in drug research and development, production and sales in the medical field and Benchmark’s advantages in cannabis cultivation and extraction.

The agreement states that Zhejiang Yatai and will make their investment in cash, and Benchmark will make their investment in intangible assets such as the licenses of cannabis cultivation, extraction, and the sales license issued by Health Canada as well as the technologies of seeds’ breeding, cultivation, extraction and its abilities in research and development.

 Key points of the agreement are as follows: 

  • the companies agree to promote and conduct research and development, production, extraction and the commercial application of CBD and its derivative products.
  • the companies agree to carry out the cultivation, planting, processing and marketing of high-content CBD industrial cannabis.
  • the companies agree to create and utilize a Canadian joint venture company as the main body to promote the research on extraction and purification processes of Cannabis and derivative products. The intellectual property obtained in the research process in Canada shall be owned by the companies.
  • the companies agree to focus on the development of a variety of cannabinoids in the commercial application field, including medicine, health care products, food, and cosmetics.
  • the companies agree to commercialize the industrialized technologies in the countries where cannabis products are legal.

A definitive agreement will be signed on or before May 30, 2019 after all due diligence work is completed and approved by regulatory authorities.

About Zhejiang Yatai Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd. is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Company’s chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has also established German commercial partnership to potentially export the Company's products into the EU markets.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF 
BENCHMARK BOTANICS INC.

/s/ "William Ying" 
William Ying 
Chief Executive Officer

Tel: 604-238-0005 Ext 101
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2019) - Benchmark Botanics Inc. (CSE: BBT) (OTC: BHHKF) (FSE: BBW) ("Benchmark" or the "Company").

Benchmark is pleased to announce that it intends to complete a non-brokered private placement for aggregate gross proceeds of $12,000,000 (the "Private Placement") with arm's-length parties and certain existing shareholders who have agreed to subscribe by issuing 30,000,000 units of the Company's securities (the "Units") at $0.40 per Unit (the "Subscription Price"). The Subscription Price represents a 5% discount to Benchmark's closing share price on April 30, 2019. Each Unit is comprised of one common share of the Company (each, a "Share") and one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant shall be exercisable into one Share at a price of $1.00 for a period of 24 months from the closing date of the Private Placement. All of the Units, Shares and Warrants will be subject to a restricted period of four months and one day from the date of closing of the Private Placement.

The Company intends to use the proceeds from the sale of the Units for general working capital purposes and the costs of setting up the Company's extraction operations. The Private Placement is subject to acceptance by the Canadian Securities Exchange.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building a second facility, a 4-acre Pitt Meadows Greenhouse Operation in BC through a joint venture (earn-in agreement) with 1139000 BC Ltd.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has also established a German commercial partnership to potentially export the Company's products into the EU markets.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it..

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005 (ext. 101)
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44474

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) ("Benchmark" or the "Company"), a cannabis producer, today released its financial and operational results for the fiscal year ended December 31, 2018.

"2018 was a truly pivotal year for Benchmark Botanics. We were issued our License to Import and License to Sell from Health Canada. The Company completed a $2,000,000 Private Placement and entered into a Trademarks License Agreement for use of the "The Bulldog" trademark in Canada. In addition, Benchmark signed a definitive agreement for the development of 4 acres of greenhouse operations in Pitt Meadows, BC and strengthened the leadership of the Company with the addition of a high-profile director and a well know industry leader," said William Ying, Benchmark Botanics President and CEO. "With this foundation in place, the Company is transitioning into a period of significant expansion with product sales, facility expansion, additional facilities being constructed, and the Asia Pacific Nutraceutical strategy being implemented. Taken together, we have strengthened our value proposition in 2018, and will be well positioned for the next stage of our growth in 2019."

2018 KEY DEVELOPMENTS

License to Import

On July 8, 2018, the Company was issued a License to Import by Health Canada. This import license allows Benchmark, through its 100% owned subsidiary Potanicals Green Growers, access to limitless genetics and strains for production. With this approved permit in hand, in July 2018 Benchmark has executed a purchase order with Dutch Passion from the Netherlands to import over 200 seeds that represent 70 different strains. This will enable Benchmark to custom produce exactly what the off-take markets are asking for. Further to this, the medical profile of the strains we are importing ranges from very high Cannabidiol (CBD) low THC, to high-THC/low-CBD, 1:1 THC: CBD strains, as well as, others. This will position the company to have many options for production when looking to service the current and future market demand.

License to Sell

On August 31, 2018, Potanicals was issued a license to sell dried cannabis under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") by Health Canada.

Non-Brokered Private Placement

On September 5, 2018, the Company closed a non-brokered private placement of 2,666,667 units (the "Units") at a price of $0.75 per Unit for aggregate gross proceeds of $2,000,000 (the "Private Placement") with an arm's-length party (the "Investor"). Each Unit is comprised of one common share of the Company ("Shares") and one common share purchase warrant ("Warrant"). Each Warrant shall be exercisable into one common share at a price of $1.20 for a period of 24 months from the closing date of the Private Placement.

License of "The Bulldog" Trademark

On September 19, 2018, the Company entered into a Trademarks License Agreement (the "Agreement") with Leidseplein Beheer B.V. (the "Licensor"), a company incorporated under the laws of the Netherlands, in which the Licensor has agreed to grant the Company use of "The Bulldog" trademark in Canada upon the terms and conditions set out in the Agreement.

Definitive Agreement with 1139000 B.C. Ltd.

The Company, together with Benchmark's wholly-owned subsidiary, Potanicals, signed a binding definitive agreement on August 30, 2018 (the "Agreement") with 1139000 B.C. Ltd. ("1139") to supersede the letter agreement with 1139 for the development of approximately 4 acres of greenhouse operations to be located in Pitt Meadows, British Columbia (the "Property") beneficially owned by 1139.

Under the terms of the Agreement, Benchmark has agreed, through Potanicals, to apply for a license under the ACMPR for the Property, and upon receipt of a license under the ACMPR will earn a 25% interest in 1139, the owner of the Property. Upon the Property being developed to a commercial stage, Benchmark will have the right to increase its ownership to 51% of 1139 in consideration for the issuance of common shares of Benchmark, such number of shares to be based on the then fair market value of 1139.

Pursuant to the Agreement, 1139 is responsible for construction of the necessary facilities on the Property for a license under the ACMPR to be obtained. Benchmark has agreed to indemnify 1139 for certain expenses relating to the acquisition of the Property and construction of the facilities if Potanicals fails to obtain a license under the ACMPR for the Property by June 30, 2019, subject to extension in certain circumstances.

KEY DEVELOPMENTS OCCURING SUBSEQUENT TO DECEMBER 31, 2018

Strengthening the management team:

Appointed Hon. James Moore as a Director.

James Moore is a Senior Business Advisor at the multinational law firm Dentons and a Public Policy Advisor at the global firm Edelman. He also serves as Chancellor of the University of Northern British Columbia, is the national vice-chair of the Canadian Cancer Society, a member of the NAFTA Council for the Government of Canada and a corporate director. Previously he served as Canada's Minister of Industry, Minister of Canadian Heritage & Official Languages and Secretary of State for the Asia Pacific Gateway and Minister for the 2010 Olympics over a 15-year career as a Member of Parliament.

Appointed of Mr. Hua Zhang PhD as Vice President of Production.

Mr. Zhang has a long and extensive history of agricultural growing and production experience. Most recently he was Head Grower and Director of Production for Hortalizas Argaman in Jalisco, Mexico where he oversaw the 135-acre farm including cucumber and tomato greenhouse production. Prior to Hortalizas Agraman, Mr. Zhang worked in Canada for 18 years which included being the Head Grower for Amoco Farms and Enns Plant Farms. He managed year-round production planning, climate and irrigation controls, labour budgeting, developing and implementing IPM strategy, personnel training and development. In 1997, he graduated with a PhD in Horticulture from Kansas State University.

OVERVIEW OF 2018 FINANCIAL RESULTS

  • Net loss for the year ended December 31, 2018 was $6,077,509, compared to a net loss of $4,437,847 for the year ended December 31, 2017. The increase in net loss for the year ended December 31, 2018 is due to the increase in operation expenses of $3,621,323, the write-off of deposit of $500,000 and the write-off of inventory of $122,450, offset by the unrealized gain on changes in fair value of biological assets of $424,259 and a reduction in an RTO list expenses of $2,179,852.

  • EBITDA before listing expenses, share-based compensation expenses, write-off of deposit, write-off of inventory and unrealized gain on changes in fair value of biological assets ("Adjusted EBITDA") for the year ended December 31, 2018 decreased to a negative $3,319,204 from a negative $1,656,275 for the same time period of last year.

  • At December 31, 2018, the Company had working capital of $793,516 (December 31, 2017-$3,069,384).

OUTSTANDING SHARE CAPITAL

As of April 29, 2018, the number of issued and outstanding common shares was 142,595,594, the number of stock options outstanding was 10,046,666, and the number of outstanding warrants was 2,666,667.

The corporation's audited annual consolidated financial statements for 2018 and the related management's discussion and analysis (MD&A) are available on SEDAR.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc., is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building a second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC through a joint venture (earn-in agreement) with 1139000 BC Ltd.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world.

Benchmark Botanics has also established German commercial partnership to potentially export the Company's products into the EU markets.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005 (ext. 101)
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44413

Vancouver, British Columbia--(Newsfile Corp. - January 28, 2019) - Benchmark Botanics, Inc. (CSE: BBT) ("Benchmark" or the "Company") is pleased to announce the addition of a well-respected agriculture industry leader Mr. Hua Zhang PhD to the Benchmark team as Vice President of Production. Mr. Zhang will provide operational expertise overseeing overall production strategies and planning as the Company continues to expand and ensure the highest quality cannabis products are produced at its Peachland Cannabis Complex and the Pitt Meadows Greenhouse Operations.

"The addition of Hua further strengthens our team and we look forward to working with this well-known industry leader,'' said William Ying CEO, Benchmark Botanics. "Professionalism and quality are central to bringing the best products to market, we welcome his expertise as we continue to grow our business around the country and into international markets."

Mr. Zhang has a long and extensive history of agricultural growing and production experience. Most recently he was Head Grower and Director of Production for Hortalizas Argaman in Jalisco Mexico where he oversaw the 135-acre farm including cucumber and tomato greenhouse production. Prior to Hortalizas Agraman, Mr. Zhang worked in Canada for 18 years which included being the Head Grower for Amoco Farms and Enns Plant Farms. He managed year-round production planning, climate and irrigation controls, labour budgeting, developing and implementing IPM strategy, personnel training and development. In 1997, he graduated with a PhD in Horticulture from Kansas State University.

Mr. Hua Zhang stated, "I'm excited about working with Benchmark Botanics and leading the Company's production in this growing and vibrant industry. Growing is my passion and I am particularly enthralled with the cannabis industry. I'm looking forward to this opportunity to make Benchmark Botanics a world leader in the cannabis industry."

The addition of Mr. Zhang is the latest example of Benchmark Botanics' strategy for building and working with the best talent in the industry. Coupled with our licensed production facilities, a rapidly expanding international medical cannabis business, and growing medical cannabis research, the Company is uniquely positioned to realize the opportunity presented by the advancement of cannabis legislation in Canada and increasingly around the world.

Benchmark on January 24, 2019 granted 450,000 stock options to Mr. Zhang and 600,000 stock options to Hon. James Moore, Benchmark's board of director announced in a news release on January 9, 2019. These options are exercisable at C$0.45 per share expiring in 5 years and vesting over a 2-year period in accordance with the terms of Benchmark's Stock Option Plan and subject to regulatory approval.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 50,000 square foot facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada.The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world. Benchmark Botanics has also entered into an agreement with Barcelona, Spain-based Green BCN Corp. ("BBG Projects") for the development and production of new strains of cannabis plant and their propagating material for future sale and distribution. Benchmark Botanics has also established German commercial partnership to potentially export the Company's products into the EU markets.

For further information, please visit the Company's website at www.benchmarkbotanics.com or the Company's profile at www.sedar.com.

If you would like to be added to Benchmark Botanics' news distribution list, please sign up at this link https://benchmarkbotanics.com/signup/ Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/42491

Vancouver, British Columbia--(Newsfile Corp. - January 9, 2019) - Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) ("Benchmark" or the "Company") is pleased to announce the appointment of Hon. James Moore to the Board of Directors. The appointment strongly positions the Company to continue with its business plan and to develop its operations and cannabis assets.

"We are pleased to welcome James to the Benchmark family as a member of our Board of Directors,'' said William Ying CEO, Benchmark Botanics. "James brings a wealth of global experience across a broad base of industry sectors and the political arena. Benchmark will greatly benefit from his professional knowledge, experience and strategic guidance."

James Moore is a Senior Business Advisor at the multinational law firm Dentons and a Public Policy Advisor at the global firm Edelman. He also serves as Chancellor of the University of British Columbia, is the national vice-chair of the Canadian Cancer Society, a member of the NAFTA Council for the Government of Canada and a corporate director. Previously he served as Canada's Minister of Industry, Minister of Canadian Heritage & Official Languages and Secretary of State for the Asia Pacific Gateway and Minister for the 2010 Olympics over a 15-year career as a Member of Parliament.

As cannabis regulatory reform continues to unfold across the globe and domestic and international opportunities emerge in its wake, Benchmark Botanics' qualified Board of Directors and management team are expected to position the Company to take full advantage of these opportunities and continue to add to its diversified portfolio of cannabis industry products and investments.

About Benchmark Botanics Inc.

Benchmark Botanics is a diversified multi-licensed cannabis producer focused on its three-way vertical business model targeting the medical, pharmaceutical, and recreational markets in Canada and the EU. The Company's business plan includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp in China and throughout Asia.

Benchmark Botanics is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark Botanics' 100% owned subsidiary, Potanicals Green Growers Inc. is a Health Canada licensed producer under the Cannabis Act and its regulations (formerly ACMPR). The Company is producing at its indoor Peachland Cannabis Complex and is in the design stage for a Phase II expansion of an additional 50,000 square foot facility. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetics and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy the company is building its second facility, a 4-acre Pitt Meadows Greenhouse Operations in BC.

The Company has established several European Union partnerships including the rights to "The Bulldog" trademark in Canada. The Bulldog trademark has a long-established successful history as one of the most well-known cannabis cafe brands in Amsterdam and around the world. Benchmark Botanics has entered into an agreement with Barcelona, Spain-based Green BCN Corp. ("BBG Projects") for the development and production of new strains of cannabis plant and their propagating material for future sale and distribution. Benchmark Botanics has also established German commercial partnership to potentially export the Company's products into the EU markets.

ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.

/s/ "William Ying"
William Ying
Chief Executive Officer

For Further Information

Investor Relations
Benchmark Botanics, Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: 604-238-0005
www.benchmarkbotanics.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.